The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TEVA | +100.64% | +183.42% | +23.14% | +12,031% |
| S&P | +13.95% | +78.35% | +12.25% | +2,827% |
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.75B | 12.4% |
| Gross Profit | $2.69B | 27.7% |
| Gross Margin | 56.49% | 6.7% |
| Market Cap | $35.79B | 43.1% |
| Market Cap / Employee | $1.07M | 0.0% |
| Employees | 33.3K | -7.8% |
| Net Income | $483.00M | 274.2% |
| EBITDA | $1.55B | 33.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.56B | 7.8% |
| Accounts Receivable | $3.71B | 21.2% |
| Inventory | 3.2K | 5.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.27B | -6.3% |
| Short Term Debt | $1.91B | 2.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.54% | 7.5% |
| Return On Invested Capital | -5.90% | -1.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.54B | 95.8% |
| Operating Free Cash Flow | $1.68B | 83.8% |
| Metric | Q3 2025 | Q4 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 32.98 | 25.64 | - | ||
| Price to Book | 3.24 | 3.07 | 3.39 | 4.94 | 19.82% |
| Price to Sales | 1.07 | 1.16 | 1.39 | 2.11 | 39.99% |
| Price to Tangible Book Value | -1.23 | -1.43 | -1.75 | -2.83 | 68.00% |
| Price to Free Cash Flow TTM | 8.55 | 16.38 | 93.61 | 36.47 | 197.91% |
| Enterprise Value to EBITDA | 35.81 | 28.85 | 29.05 | 32.38 | -6.10% |
| Free Cash Flow Yield | 11.7% | 6.1% | 1.1% | 2.7% | -66.43% |
| Return on Equity | -19.0% | -2.4% | 10.8% | 21.4% | -183.92% |
| Total Debt | $16.94B | $17.52B | $17.07B | $17.19B | -5.38% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
